Deborah Autor Sells 16,773 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Posted by Francis Steltz on Aug 22nd, 2026

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Deborah Autor sold 16,773 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total value of $467,128.05. Following the completion of the transaction, the insider owned 48,961 shares of the company’s stock, valued at approximately $1,363,563.85. The trade was a 25.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $33.67 on Friday. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $65.30. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The company has a market capitalization of $7.86 billion, a price-to-earnings ratio of -53.44 and a beta of 2.40. The business has a 50 day simple moving average of $32.37 and a 200-day simple moving average of $26.14.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business’s revenue for the quarter was up 38.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.17 earnings per share. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors have recently modified their holdings of HIMS. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health in the 3rd quarter worth about $28,000. Versant Capital Management Inc boosted its stake in Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after purchasing an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB boosted its stake in Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares during the period. Silicon Valley Capital Partners bought a new position in Hims & Hers Health in the 3rd quarter worth about $48,000. Finally, Bogart Wealth LLC grew its position in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

HIMS has been the subject of several research reports. Morgan Stanley lifted their price target on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a report on Tuesday, August 11th. Truist Financial increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Finally, JPMorgan Chase & Co. lowered their target price on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $32.17.

Check Out Our Latest Research Report on HIMS

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Analysts and investors see continued expansion opportunities in branded GLP-1 weight-loss products, testosterone, peptides, international markets and AI-driven patient support. These initiatives could strengthen revenue growth and improve operating efficiency over time. What is driving HIMS stock’s rally
Positive Sentiment: Barclays maintained an “overweight” rating, indicating a favorable long-term view even after reducing its price target from $39 to $35. The revised target remains above the referenced trading level. Barclays price-target update
Neutral Sentiment: Recent insider sales by CFO Oluyemi Okupe and other executives were made under pre-arranged Rule 10b5-1 plans. While the transactions may create a modest overhang, the insiders continued to hold sizable positions, reducing the signal that management confidence has materially weakened. HIMS insider sales
Neutral Sentiment: Analyst views remain divided. Needham raised its price target to $42 and kept a Buy rating, while the broader consensus remains Hold, reflecting strong revenue growth but uncertainty around margins and the GLP-1 strategy.
Negative Sentiment: Three law firms announced investigations into potential securities-law violations. These announcements are investor outreach notices—not findings of wrongdoing—but they add legal, compliance and reputational risk amid scrutiny of privacy practices, billing and subscription cancellations. Kaplan Fox investigation
Negative Sentiment: The latest quarterly results showed revenue of $753.2 million, up 38.2% year over year and above expectations, but the company reported a $0.37-per-share loss versus the expected $0.05 loss. Persistent losses and weak profitability could limit further upside unless margins improve.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.